James Silverman
@Opaleye Management Inc.
Latest period2024 - Q3ReportedManaged Assets$599.558MTotal holdings44
Assets growth rate37%Assets growth rate (2-Q avg)16.19%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Opaleye Management Inc.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 44 positions.
Assets under management
The assets under management (AUM) of Opaleye Management Inc. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 599.558M in assets, with a quarterly growth rate of 37% and a 2-quarter average growth rate of 16.19%. The portfolio is managed by James Silverman, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
HROWHarrow Health Inc
| 29.93% | $179.39M 3.99M shares@ $44.96 avg price | |
TGTXTg Therapeutics Inc
| 8.9% | $53.329M 2.28M shares@ $23.39 avg price | |
OCULOcular Therapeutix Inc
| 7.3% | $43.718M 5.025M shares@ $8.7 avg price | Decreased -5.32% |
ARVNArvinas Inc
| 5.16% | $30.911M 1.255M shares@ $24.63 avg price | Increased 126.13% |
CDXSCodexis Inc
| 4.51% | $27.012M 8.77M shares@ $3.08 avg price | Increased 153.84% |
RYTMRhythm Pharmaceuticals Inc
| 4.37% | $26.195M 500,000 shares@ $52.39 avg price | Decreased -2.91% |
KROSKeros Therapeutics Inc
| 3.83% | $22.954M 395,276 shares@ $58.07 avg price | Increased 7.56% |
IMNMImmunome Inc
| 3.02% | $18.092M 1.238M shares@ $14.62 avg price | Increased 12.25% |
LQDALiquidia Corporation
| 2.84% | $16.981M 1.698M shares@ $10.0 avg price | Increased 422.51% |
ETONEton Pharmaceuticals Inc
| 2.79% | $16.68M 2.78M shares@ $6.0 avg price | Increased 16.08% |